Practice

Linda Pissott Reig is a principal of the Porzio Bromberg & Newman law firm (Morristown, NJ and New York City) and Vice President of Compliance Services for Porzio Pharmaceutical Services. Ms. Reig has extensive experience with the laws and industry standards relating to the marketing and sale of prescription drugs, medical devices and biologics. She worked for many years in Porzio’s Key Client program where she served as part of the in-house legal team of a pharmaceutical company several days a week. She drafts agreements with vendors, consultants and other third parties, reviews promotional materials, conducts training, provides business advice on consulting agreements and advisory boards, and evaluates continuing medical education and other sponsorship opportunities. She evaluates compliance programs and company practices in connection with annual declarations required by state law, as well as develops work plans for development of comprehensive compliance programs for companies preparing to launch an FDA-approved product for the first time.

In addition, she has assisted companies in complying with requirements associated with state marketing disclosure reporting laws. She also reviews opportunities to work with key opinion leaders, enter into consulting arrangements or provide financial support for programs focused on education or research. She regularly counsels clients on the various federal statutes that impact these areas, including the Food, Drug and Cosmetic Act, the Patient Protection and Affordable Care Act, the Food & Drug Administration Modernization Act of 1997, the Anti-Kickback Statute and False Claims Act, as well as applicable state laws. Her experience with industry standards includes the PhRMA Code on Interactions with Healthcare Professionals, the AdvaMed Code of Ethics for Interactions with Health Care Professionals, the ACCME Standards for Commercial Support and AMA ethical opinions. She also evaluates gifts to physician, use of market research services, interactions with managed care organizations, pre-approval communications, promotion over the Internet and evaluation of post-marketing adverse events and implementation of labeling changes. Ms. Reig's past experience as a Litigator included defense of pharmaceutical and life sciences products in products liability, class action and consumer fraud lawsuits, as well as commercial and employment matters.

Ms. Reig is a summa cum laude graduate of Rutgers Newark College of Arts & Sciences, and cum laude graduate of Georgetown University Law Center. Following law school, Ms. Reig was a judicial law clerk with then New Jersey Supreme Court Justice Marie L. Garibaldi.  She is a past Chairman of the Board of the New Jersey Defense Association, and past chairperson of the NJDA’s Products Liability Committee. She also is a member of the Defense Research Institute’s Drug & Medical Device Committee and the NJ State Bar Association Appellate Practice Committee.

Prior Relevant Experience

• Norris, McLaughlin & Marcus, Associate Attorney, civil litigation, including commercial litigation, lender liability and foreclosures, employment law, professional malpractice, and products liability law, 1994–1997
• The Honorable Marie L. Garibaldi, New Jersey Supreme Court, Judicial Clerk, 1993–1994
• Congressman H. James Saxton, Washington, D.C., Staff Assistant, 1992
• Crummy, Del Deo, Dolan, Griffinger & Vecchione, Summer Associate, 1992
• U.S. Attorney’s Office, Transnational/Major Crimes & Civil Divisions, Washington, D.C., Law Clerk, 1991

Opinions, Decisions and Cases

• Thiedemann v. Mercedes-Benz USA, LLC, 183 N.J. 234, 872 A.2d 783 (2005)
• West Morris Pediatrics v. Henry Schein, Inc., 385 N.J. Super. 581, 897 A.2d 1140 (Law Div. 2004)
• Estate of Frankl v. Goodyear Tire & Rubber Co., 181 N.J. 1; 853 A.2d 880 (2004)
• Erny v. Estate of Merola, 171 N.J. 86; 792 A.2d 1208 (2002)

Honors and Awards

• Recognized by New Jersey Law Journal in their annual “40 Under 40” list of attorneys (August 6, 2007)
• Recognized by New Jersey Monthly Magazine as a "Rising Star" in the State of New Jersey, 2006 -2008
• Martindale-Hubbell Law Directory, AV Rating
• Award Recipient, Alumni Meritorious Service Award presented by the Rutgers University Alumni Federation, October 15, 2004.

Organizations/Memberships

• New Jersey State Bar Association, 1993–present
• New Jersey State Bar Association, Product Liability and Toxic Tort Section, 1998–present
• New Jersey State Bar Association Appellate Practice Committee, 2005–present
• American Bar Association, Litigation Section; Corporate Counsel Committee; Co-chair, membership (2004–present), New Jersey State Liaison (2003–2004), Women Advocate Committee; Health Law Section
• Morris County Bar Association, 1997–2002
• Semi-Finalist, Morris County Young Lawyers Mock Trial Competition, 1998
• American Health Lawyers Association, 2000–2001
• Defense Research Institute, 2003 Annual Meeting Steering Committee Member
• Defense Research Institute Drug and Medical Device Committee, 1998–2008
• Defense Research Institute State and Local Defense Organizations, Young Lawyers Committee Representative for New Jersey, 2000–2003
• Defense Research Institute, Technology Committee Editor for the For the Defense Monthly Magazine, 2000–2004
• New Jersey Defense Association, Chairman of the Board, 2006–2007; President, 2005–2006; President-Elect, 2004–2005; Secretary/Treasurer, 2003–2004; Member, Board of Directors, 2002–2003; Regional Vice President (Northern Region), 2000–2002; Products Liability Committee Chairperson, 2001–2004; Long Range Planning Committee Chairperson, 2000–present; Amicus Curiae Co-chairperson, 2002–present; Young Lawyers Committee Chairperson, 1999–2000
• Joseph Halpern American Inn of Court, Graduate, 1996–1997
• Rutgers Newark College of Arts and Sciences Alumni Association, President, 2002–2003, Vice President, 2000–2002, Young Alumni Committee Chairperson, 1995–2000; Executive Committee Member, 1994–2003
• Rutgers University Alumni Federation Representative, 2000–2003, Constituents’ Concerns Committee Chairperson, 2001–2003
• Georgetown University Undergraduate Admissions Program, Interviewer, 1995–2003
• Georgetown Club of Northern New Jersey, Member, 2002–2004
• Georgetown National Law Alumni Board, 2005–present
• The American Law Institute, 2006–present
• New Jersey Women Lawyers Association, 2010

Publications

• "Off-Label Compliance: Training and Monitoring Sales and Marketing Personnel," FDLI Off-Label Communications: A Guide to Sales & Marketing Compliance, 2008, 2009.
• “Issued Less Frequently, DDMAC Letters Still Offer Valuable Lessons,” Regulatory Focus, Vol. 13, No. 7, July 2008.
• "New Era in Prescription Drug Liability:  The Learned Intermediary Doctrine in the Wake of West Virginia's Karl Decision," New Jersey Defense Association, Vol. 24, Issue 2, May 2008.
• “What is a Drug Company To Do? – Preemption and the Quandary of State Law Claims that Second-Guess FDA Labeling Determinations,” New Jersey Defense, Volume 24, Issue 1, November 2007.
• “DDMAC Reasserts Its Oversight of Promotion Directed Not Only to Physicians, But Also to P&T Committees,” Porzio Pharmaceutical Alert, Volume III, No. 4, September 11, 2007. Reprinted in Rx Compliance Report, Vol. VI, Issue 17, November 7, 2007.
• “Newly Enacted Nevada Statute Requires Adoption of a Marketing Code of Conduct.” Porzio Pharmaceutical Alert, Volume III, No. 3, June 18, 2007.
• “Courts’ Misapplication of FDA Preemption Policy Creates Quandary for Drug Producers,” Washington Legal Foundation, Legal Backgrounder, Vol. 22, No. 9, March 9, 2007.  Reprinted in Mealey's Antidepressant Drugs Litigation Report, Vol. 3, Issue 8, March 2007, and in Andrews Pharmaceutical Litigation Reporter, Vol. 23, Issue 5, July 2007.
• "Porzio's Review of DDMAC Untitled and Warning Letters on Rx Drug Promotion," Porzio Pharmaceutical Alert, Volume III, No. 2, February 26, 2007.
• "FDA to 'Redouble' Enforcement Efforts Against Marketed Unapproved Drugs," Porzio Pharmaceutical Alert, Vol. III, No. 1, January 11, 2007.
• "Preemption: Standoff at the Crossroads of Federal Drug Labeling Regulation and State Product Liability Law," Pharmaceutical Law & Industry Report, Vol. 4, No. 49, December 22, 2006.
• "Warnings to the Patient by a Prescriber in Pharmaceutical Litigation — Proof Through Habit Evidence," For the Defense, Defense Research Institute, November 2006.
• “Between a Rock and a Hard Place—Off Label Communications in an Era of Clinical Trial Registries, Continuing Medical Education Scrutiny and Medicare Part D,” Regulatory Affairs Focus, Vol. 11, No. 11, November 2006.
• “Porzio’s Quarterly Review of DDMAC Untitled & Warning Letters on Rx Drug Promotion: DDMAC Launches a Broadbased Attack on a Wide Range of Promotional Materials,” Porzio Pharmaceutical Alert, Vol. II, No. 4, May 8, 2006.
• “Caught in the Rx Drug Web: Recent Proposals to Restrict Direct-to-Consumer Advertising of Restricted Devices,” FDLI Update, Issue 2, March/April 2006.
• “Porzio’s Quarterly Review of DDMAC Untitled & Warning Letters on Rx Drug Promotion: Omit Risk Information At Your Peril,” Porzio Pharmaceutical Alert, Vol. II, No. 1, January 20, 2006.
• “Expanded Liability Exposure for Drug and Medical Device Manufacturers: Uninjured Plaintiffs Seek Recovery for ’Artificially Inflated Prices’ or Other Relief,” LJN’s Product Liability Law & Strategy Newsletter, December 2005.
• “Will Proposed Restrictions on Drug Advertising Leave Patients in the Dark? An Overview of Proposals to Limit Direct-to-Consumer Advertising of Prescription Drugs,” Porzio Pharmaceutical Alert, Vol. I, No. 2, December 20, 2005.
• “Porzio’s Quarterly Review of DDMAC Untitled & Warning Letters on Rx Drug Promotion: ‘Hot Button’ Issues for The FDA in Drug Advertising & Promotion,” Porzio Pharmaceutical Alert, Vol. I, No. 1, October 31, 2005.
• “Opening Pandora’s Box: Unregulated On-Line Pharmacy Operations and Legalized Drug Importation,” FDLI Update, Issue 4, July–August 2005.
• “The Class Action Fairness Act of 2005: Overview, Historical Perspective, and Settlement Requirements,” Tort Trial & Insurance Practice Law Journal, American Bar Association, Vol. 40, No. 4, Summer 2005.
• “Avoiding Legal and Ethical Pitfalls of Industry-Sponsored Research: The Co-Existence of Research, Scholarship and Marketing in the Pharmaceutical Industry,” Food and Drug Law Journal, Volume 59, Number 4, Fall 2004.
• “Training & Policing the Sales Representatives: Creative Tactics for an Effective Compliance Program,” American Conference Institute seminar handout, October 25, 2004.
• “Legally Getting the Word Out: Use of Press Releases and Websites to Publicize Scientific Advances Before FDA Approval of New Drugs or New Indications,” American Conference Institute seminar handout, June 21, 2004.
• “Advances in Technology—Transforming the Practice of Law,” For the Defense, Defense Research Institute, June 2004.
• “Appellate Division Rejects ‘Fraud on the Market’ and ‘Artificial Price Inflation’ Theories of Recovery Under the New Jersey Consumer Fraud Act,” New Jersey Defense, Volume 20, Issue 2, Spring 2004.
• “Industry-Sponsored Research: What You Need to Know to Avoid Legal Pitfalls in the Communication of Clinical Trial Results,” Medical Research Law & Policy Report, Bureau of National Affairs, Inc., March 17, 2004.
• “Amicus Curiae Victorious: Ex-Parte Physician Interviews Not Preempted by HIPAA,” New Jersey Defense, Vol. 20, Issue 1, 2003.
• “Moving Ahead With Technology,” For the Defense, Defense Research Institute, December 2001.
• “The Learned Intermediary Doctrine,” For the Defense, Defense Research Institute, June 2001.
• “A Tribute to the Honorable Marie L. Garibaldi,” Seton Hall Law Review, Vol. 31, No. 1, 2000.
• “Scientists Under a Microscope: Practical Tips for Critically Analyzing Medical Literature,” Rx for the Defense, Defense Research Institute Drug & Medical Device Committee Newsletter, Summer 2000.
• “Doctor Still Knows Best: Safeguarding the Learned Intermediary Doctrine in a New Era of Consumer Advertising,” Drug & Medical Device Litigation Defense Practice Seminar Course Book, Defense Research Institute, April 1999.
• “Drug Ads and the Learned Intermediary Doctrine,” New Jersey Lawyer, February 15, 1999.
• “Chemical Sensitivity,” Claims Vulnerable to Daubert Scrutiny—Legal Backgrounder, Washington Legal Foundation, May 15, 1998.
• “The Amortization of Customer-Based Intangibles: The “Separate and Distinct from Goodwill” Requirement and H.R. 3035’s Proposal for Change,” The Tax Lawyer, Summer 1992.
• Commentator for Rx Compliance Report, NJ Lawyer and NJ Law Journal.

Speaking Engagements

• "Minimizing Product Liability Risk in the European Union and the USA," The Drug Information Association Annual Meeting, Washington, DC, June 14, 2010.
• "State Marketing Laws Affecting Drug & Device Companies," Seton Hall Law Healthcare Compliance Certification Program, Newark, NJ, June 7, 2010.
• "Federal Healthcare Reform," Seton Hall Law Healthcare Compliance Certification Program, Newark, NJ, June 7, 2010.
• "Compliance Issues with Clinical Trials & Communicating Clinical Trial Results," New Jersey Corporate Counsel Association (NJCCA), Basking Ridge, NJ, May 6, 2010.
• "Clinical Trial Agreement Negotiation: Key Elements for Sponsors," New Jersey Corporate Counsel Association (NJCCA), Basking Ridge, NJ, May 6, 2010.
• "The Evolving Role of Medical Science Liaisons and Avoiding Abuse in the Conduct and Use of Clinical Trials," ACI's Fraud and Abuse in the Sale and Marketing of Drugs Conference, New York, NY, March 25, 2010.

• "Medical Affairs Boot Camp - Legal, Regulatory & Compliance Fundamentals Necessary to Departmental Functions and Infrastructure," ACI Medical Affairs Conference, Philadelphia, PA, December 7-8, 2009.

• "Lawful Pre-Approval Communication: How to Avoid the Appearance of Unlawful Promotion," New York State Bar Association - Food, Drug and Cosmetic Law Section,
  New York, NY, October 29, 2009. 

• "Healthcare Reform Scramble: State and Federal Regulations Affecting the Sales & Marketing Practices of Drug & Medical Device Companies," Seton Hall Law Healthcare Compliance Certification Program, Newark, NJ, October 26, 2009.
• “Promotional Review,” Fifth Annual Porzio Compliance Forum, Porzio Pharmaceutical Services, LLC, Basking Ridge, NJ, October 7, 2009.
• "NJ LEEP Summer Law Institute," Seton Hall Law School, Newark, NJ, July 28, 2009.
• "Funding Biopharma: Strategies for Reaching Investors in a Financial Crisis," (Regulation & Profitability Panelist), Basking Ridge Country Club, Basking Ridge, NJ, June 9, 2009.
• "Anything You Can Do I Can Do Better - State Regulation of Drug & Medical Device Companies," Seton Hall Law Healthcare Compliance Certification Program, Newark, NJ, June 8, 2009.
• "Divergent State Marketing Disclosure & Limitation Laws – Tackling the Compliance Challenge," ACI’s 9th National Forum on Fraud & Abuse in the Sale and Marketing of Drugs, Helmsley Park Lane, NY, April 20, 2009.
• "Practical Tips for Minimizing Risk in Advertising and Promotion Analysis and Overview of 2008 FDA Untitled and Warning Letters & Other Topics," Regulatory Affairs Professionals Society (RAPS) Webcast, April 15, 2009.
• “Wyeth v. Levine:  What You Should Do Now Regarding Preemption,” ThompsonInteractive Audio Conference, April 9, 2009.
• "Practical Tips for Minimizing Risk in Advertising and Promotion Analysis and Overview of 2008 FDA Untitled and Warning Letters & Other Topics," Regulatory Affairs Professionals Society (RAPS) NY/NJ Chapter, East Hanover, NJ, February 26, 2009.
• "The Times They Are A-Changin’ -  State Laws Restricting Use of Prescriber-Level Rx Data," CBI’s Premier Forum on Marketing Data Analytics for the Pharmaceutical Industry, Philadelphia, PA, January 27, 2009.
• “FDA Preemption: What's Happening and What Does it Mean for Me?,” ThompsonInteractive Audio Conference, July 29, 2008.

• “Minimizing the Potential for Off-Label Violations when Engaging in Risky Activities: Medical Meetings, Publication Planning and Sensitivity in Corporate Communications,” ACI’s 5th Annual Pharmaceutical & Medical Device Manufacturers’ Guide to Off-Label Communications, Philadelphia, PA, July 16, 2008.

• “A New Era of Transparency: Mastering State Laws on Marketing & Sales Compliance,” Seton Hall Law Healthcare Compliance Certification Program, Newark, NJ, June 16, 2008.
• “Utilization of Medical Liaisons & Publication Planning in Promotional Messaging,” CBI’s 2nd Annual Forum Bio/Pharmaceutical and Medical Device Promotional Programs, Philadelphia, PA, May 29, 2008.

• “Avoiding Pitfalls in Off-Label Communications and Effective Use of Medical Science Liaisons,” Regulatory Affairs Professionals Society (RAPS) Advertising, Promotion and Labeling Conference, Baltimore, MD, May 12, 2008.

• “An Ever Increasing Burden:  Clinical Trial & Marketing Disclosure Requirements Under State &  Federal Law,” Regulatory Affairs Professionals Society (RAPS) Advertising, Promotion and Labeling Conference, Baltimore, MD, May 13, 2008.
• "State Specific Rules: Real-life Scenarios for Aggregate Spend Compliance," HCPro Webinar, April 18, 2008.
• "A New Era of Transparency: Mastering State Laws on Marketing & Sales Compliance," Seton Hall Law's Health Care Compliance Certification Program, Newark, NJ, February 25, 2008.
• “Update on Preemption of State Product Liability Lawsuits & How to Ensure Your National Advertising and Marketing Practices are in Compliance with State Laws," ACI's 6th Annual Corporate Counsel Forum on Advertising & Promotions for the Pharmaceutical Industry, New York, NY, January 22, 2008.
• “An Update on State and Federal Regulations –Their Impact on Publication Planning," 3rd Annual Forum on Strategic Publication Planning, Center for Business Intelligence, Philadelphia, PA, December 5, 2007.
• “Who Says It's Not the Conscientious ‘Everybody’ Protection Act? An Update on Independent Contractor Status and New Jersey’s CEPA (Whistleblower) Law,” BioNJ Human Resources Forum, “Protecting the Company and the Workforce,” Porzio, Bromberg & Newman, Morristown, NJ, November 13, 2007.
• “State Marketing, Ethics and Disclosure Laws Track: Overview of State Marketing Laws and Regulations," 8th Annual Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum: Transformational Learning - Effective Knowledge Exchange, Washington, DC, November 8, 2007.
• “Only ‘Foolish’ Consistency is the Hobgoblin of Little Minds – Minimizing Product Liability Risk through Consistent Capture, Consideration and Communication of Postmarketing Adverse Events," Drug Information Association’s (DIA) Conference on Leveraging Knowledge Management, a Focus on Product Cross-Licensing, Product Liability & Pharmacovigilance, Madrid, Spain, October 17, 2007.
• “Developing Influence in the Executive Suite,” Women’s Breakfast Roundtable, Third Annual Porzio Compliance Forum, Porzio Pharmaceutical Services, LLC, Basking Ridge, NJ, September 26, 2007.
• “Aggregate Expense Tracking in the States,” Third Annual Porzio Compliance Forum, Porzio Pharmaceutical Services, LLC, Basking Ridge, New Jersey, September 26, 2007.

• "Between a Rock and a Hard Place: FDA's Labeling Rule and Liability Lawsuits," FDAnews audioconference, June 27, 2007.

• “The Mid-Year State Compliance Update: Hot Topics and New Developments,” ePharmaceuticals (a division of HCPro, Inc.) Webinar, June 12, 2007.
• "Off-Label Communications: CME Activities & Clinical Trial Registries," Advertising, Promotion and Labeling Conference, Regulatory Affairs Professionals Society, Minneapolis, MN, May 10, 2007.
• "Getting Down to Specifics: Training Sales Reps on the Hot-Button Issues in Recent Investigations," ACI's Drug and Device Compliance Boot Camp: Training the Sales Force, New York, NY, April 12, 2007.
• "The Future of Biotechnology: Economics, Public Health, Ethics and State/National Interests," Georgetown Club of Northern New Jersey, Morristown, New Jersey, September 27, 2006.
• “Between a Rock and a Hard Place—Off Label Communications in an Era of Clinical Trial Registries, CME Scrutiny and Medicare Part D,” Second Annual Porzio Compliance Forum, Porzio Pharmaceutical Services, LLC, Basking Ridge, New Jersey, September 13, 2006.
• “Recent Trends in FDA Untitled and Warning Letters & Avoiding Misleading Use of Medical Data,” Fourth Annual In-House Counsel & Regulatory Forum: Minimizing Legal Risks in Drug Advertising and Promotion, American Conference Institute, Philadelphia, Pennsylvania, March 13, 2006.
• “So Much to Do, So Little Time—Setting Priorities for Your Pharmaceutical Company’s Compliance Program,” Building an Effective Business Conduct and Compliance Program Workshop, CBI’s 3rd Annual Pharmaceutical Marketing Compliance Congress, Washington, DC, January 30, 2006.
• “State Legislation: Complying with Current Requirements and Preparing for the Future,” Fraud & Abuse in the Sale & Marketing of Drugs Conference, American Conference Institute, New York, New York, October 24–25, 2005.
• Co-Chair, “National Forum on Off-Label Promotion of Pharmaceuticals,” and Speaker, “State Law Update: Clinical Trial Registries, Sampling (Mid-Level Practitioners & Theft/Loss Reporting), Price Disclosures & Advertising Cost Disclosures,” American Conference Institute, Philadelphia, Pennsylvania, September 21–23, 2005.
• “Keeping an Eye on the New ’Sheriffs’—State Law Activity Involving Pharmaceutical Marketing Disclosures,” First Annual Porzio Compliance Forum, Porzio Pharmaceutical Services, LLC, Bedminster, New Jersey, September 14, 2005.
• “The Thrill of Victory is Within Your Reach: Avoiding Treble Damages Under State Consumer Fraud & Unfair Trade Practices Laws,” Third Annual Conference on Minimizing Legal Risks in Drug Advertising and Promotion: Practical Strategies for Compliance & Defense, American Conference Institute, Philadelphia, Pennsylvania, June 13, 2005.
• “Recent Prosecutions and Key Considerations Associated With the Sale and Marketing of Products,” New Jersey Corporate Counsel Association’s Legal Express Super Course, New Brunswick, New Jersey, May 12, 2005.
• Moderator, “Becoming First Chair: Techniques for Young Lawyers,” American Bar Association, Litigation Section Annual Conference, New York, New York, April 23, 2005.
• “Off Label Communications and Continuing Legal Education—Protected Medical Discourse or Illegal Drug Promotion,” In-House Pharmaceutical Marketing and Sales Compliance Department Training, Morristown, New Jersey, March 14, 2005.
• “Taking Damage Awards To Infinity & Beyond? Recent Lawsuits Involving Claims by Non-Injured Parties,” Presenter and Moderator, Food & Drug Law Institute (“Product Liability for FDA-Regulated Products: In What Kind Of World Are We Living?,” conference), Washington, D.C., January 26–27, 2005.
• “From Sales Representation to Upper Management: Strategies for Achieving a Culture of Compliance Within Your Company,” (Workshop) American Conference Institute, Philadelphia, Pennsylvania, October 27, 2004.
• “Training and Policing the Sales Reps,” American Conference Institute, Philadelphia, Pennsylvania, October 25, 2004.
• “A ‘Better Mousetrap’ Revisited: Using Recent Developments in Products Liability Law to the Defense Attorney’s Advantage,” New Jersey Defense Association’s Annual Convention, Newport, Rhode Island, June 25, 2004.
• “Minimizing the Risks of Pre-Approval Promotion and Communication about Clinical Trials,” American Conference Institute, Philadelphia, Pennsylvania, June 21, 2004.
• “Defect or Deception?—Assessing Consumer Fraud Act Claims in Failure to Warn Product Liability Actions,” presentation at the Product Liability 2004 Extreme Makeover: A Fresh Look at Key Issues & Trends in the Law Seminar, New Jersey Institute for Continuing Legal Education, New Brunswick, New Jersey, May 15, 2004.
• “Regulation of Drug Marketing,” Seminar and Workshop, Food & Drug Law Institute, New Brunswick, New Jersey, April 30, 2004.
• “Industry-Sponsored Research: What You Need to Know to Avoid Legal Pitfalls—Standards on Communication of Clinical Trial Results, ‘Hands On’ versus ‘Hands Off’ Role in Drafting Medical Literature & Practical Tips for Preventing Unwanted Access to Study Data,” American Conference Institute, Washington, D.C., February 9, 2004.
• “New Jersey Consumer Fraud Act Case Law Update (January 2002–June 2003),” New Jersey Defense Association’s Annual Convention, Washington, D.C., June 28, 2003.
• “Avoiding Legal and Ethical Pitfalls of Industry-Sponsored Research and ‘Ghostwritten’ Articles,” American Conference Institute, Philadelphia, Pennsylvania, June 3, 2003.
• Moderator,New Jersey Defense Association Product Liability Seminar, Iselin, New Jersey, October 14, 2002.
• “Taking Treble Damages Out of the Mix: Defending Against Consumer Fraud Act Claims in Product Liability Cases,” New Jersey Defense Association Annual Convention, Lake George, New York, June 28, 2002.
• “Navigating Legal Issues in Cyberspace,” The New Jersey-Pennsylvania Council of AeA and the Ironbound Business Organization, Newark, New Jersey, July 2001.
• “Scientists Under a Microscope: Practical Tips for Critically Analyzing Medical Literature,” Drug & Medical Device Section of the Defense Research Institute—Young Lawyers Program, April 2000.